Grifols (NASDAQ:GRFS) Shares Gap Up – Should You Buy?

Grifols, S.A. (NASDAQ:GRFS) gapped up prior to trading on Wednesday . The stock had previously closed at $6.96, but opened at $7.22. Grifols shares last traded at $7.15, with a volume of 437,796 shares trading hands.

Wall Street Analyst Weigh In

Separately, Morgan Stanley began coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Price Performance

The company’s 50 day moving average price is $7.54 and its 200 day moving average price is $8.00. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a market cap of $4.89 billion, a price-to-earnings ratio of 6.08 and a beta of 0.35.

Institutional Investors Weigh In On Grifols

A number of large investors have recently bought and sold shares of GRFS. JPMorgan Chase & Co. boosted its stake in Grifols by 144.0% in the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after purchasing an additional 1,181,959 shares in the last quarter. Helikon Investments Ltd bought a new position in shares of Grifols in the fourth quarter valued at about $580,000. Stifel Financial Corp acquired a new position in Grifols during the 3rd quarter worth about $1,043,000. GAMMA Investing LLC raised its stake in shares of Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,527 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Grifols during the third quarter valued at $363,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.